Pinocytosis as the Biological Mechanism That Protects Pgp Function in Multidrug Resistant Cancer Cells and in Blood-Brain Barrier Endothelial Cells

Cancer is the second leading cause of death worldwide. Chemotherapy has shown reasonable success in treating cancer. However, multidrug resistance (MDR), a phenomenon by which cancerous cells become resistant to a broad range of functionally and structurally unrelated chemotherapeutic agents, is a major drawback in the effective use of chemotherapeutic agents in the clinic. Overexpression of P-glycoprotein (Pgp) is a major cause of MDR in cancer as it actively effluxes a wide range of structurally and chemically unrelated substrates, including chemotherapeutic agents. Interestingly, Pgp is also overexpressed in the endothelial cells of blood–brain barrier (BBB) restricting the entry of 98% small molecule drugs to the brain. The efficacy of Pgp is sensitive to any impairment of the membrane structure. A small increase of 2% in the membrane surface tension, which can be caused by a very low drug concentration, is enough to block the Pgp function. We demonstrate in this work by mathematical equations that the incorporation of drugs does increase the surface tension as expected, and the mechanism of endocytosis dissipates any increase in surface tension by augmenting the internalisation of membrane per unit of time, such that an increase in the surface tension of about 2% can be dissipated within only 4.5 s.

[1]  Huirong Shi,et al.  Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. , 2017, Oncotarget.

[2]  C. Rauch The “Multi” of Drug Resistance Explained by Oscillating Drug Transporters, Drug–Membrane Physical Interactions and Spatial Dimensionality , 2011, Cell Biochemistry and Biophysics.

[3]  F. Shephard,et al.  Importance of the Difference in Surface Pressures of the Cell Membrane in Doxorubicin Resistant Cells That do not Express Pgp and ABCG2 , 2013, Cell Biochemistry and Biophysics.

[4]  H. Saragovi,et al.  Novel approaches for targeted cancer therapy. , 2004, Current cancer drug targets.

[5]  R. Assoian,et al.  ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition. , 2008, Cancer research.

[6]  O. Jensen,et al.  On a biophysical and mathematical model of Pgp-mediated multidrug resistance: understanding the “space–time” dimension of MDR , 2009, European Biophysics Journal.

[7]  A. Pluen,et al.  Multi drug resistance-dependent “vacuum cleaner” functionality potentially driven by the interactions between endocytosis, drug size and Pgp-like transporters surface density , 2007, European Biophysics Journal.

[8]  C. Rauch,et al.  Acid-mediated Lipinski’s second rule: application to drug design and targeting in cancer , 2014, European Biophysics Journal.

[9]  Ashraf N. Abdalla,et al.  Design, synthesis, and in vitro biological evaluation of 14-hydroxytylophorine-dichloroacetate co-drugs as antiproliferative agents. , 2019, Chemical & pharmaceutical bulletin.

[10]  N. Johnson,et al.  Systemic cancer therapy: achievements and challenges that lie ahead , 2013, Front. Pharmacol..

[11]  J. González-Ros,et al.  Ultrastructural alterations in plasma membranes from drug-resistant P388 murine leukemia cells. , 1990, Biochimica et biophysica acta.

[12]  S. Paine,et al.  Can long range mechanical interaction between drugs and membrane proteins define the notion of molecular promiscuity? Application to P-glycoprotein-mediated multidrug resistance (MDR). , 2013, Biochimica et biophysica acta.

[13]  David J. Begley,et al.  Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.

[14]  C. Rauch On the relationship between drug’s size, cell membrane mechanical properties and high levels of multi drug resistance: a comparison to published data , 2009, European Biophysics Journal.

[15]  M. Melamed,et al.  Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[16]  C. Rauch,et al.  Physical and biological characteristics of multi drug resistance (MDR): An integral approach considering pH and drug resistance in cancer. , 2017, Seminars in cancer biology.

[17]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[18]  W. Pardridge The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[19]  Jean-Pierre Gillet,et al.  Mechanisms of multidrug resistance in cancer. , 2010, Methods in molecular biology.

[20]  E. Farge,et al.  Endocytosis switch controlled by transmembrane osmotic pressure and phospholipid number asymmetry. , 2000, Biophysical journal.

[21]  A. Mobasheri,et al.  On Some Aspects of the Thermodynamic of Membrane Recycling Mediated by Fluid Phase Endocytosis: Evaluation of Published Data and Perspectives , 2010, Cell Biochemistry and Biophysics.